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Abstract
Background: Allergic disease can be characterized as manifestations of an exaggerated inflammatory response to
environmental allergens triggers. Mite allergen Der-p2 is one of the major allergens of the house dust mite, which
contributes to TLR4 expression and function in B cells in allergic patients. However, the precise mechanisms of Der-p2 on B
cells remain obscure.
Methodology/Principal Findings: We investigated the effects of Der-p2 on proinflammatory cytokines responses and Toll-
like receptor-4 (TLR4)-related signaling in human B cells activation. We demonstrated that Der-p2 activates pro-
inflammatory cytokines, TLR4 and its co-receptor MD2. ERK inhibitor PD98059 significantly enhanced TLR4/MD2 expression
in Der-p2-treated B cells. Der-p2 markedly activated mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) and
decreased p38 phosphorylation in B cells. MKP-1-siRNA downregulated TLR4/MD2 expression in Der-p2-treated B cells. In
addition, Der-p2 significantly up-regulated expression of co-stimulatory molecules and increased B cell proliferation.
Neutralizing Der-p2 antibody could effectively abrogate the Der-p2-induced B cell proliferation. Der-p2 could also markedly
induce NF-kB activation in B cells, which could be counteracted by dexamethasone.
Conclusions/Significance: These results strongly suggest that Der-p2 is capable of triggering B cell activation and MKP-1-
activated p38/MAPK dephosphorylation-regulated TLR4 induction, which subsequently enhances host immune, defense
responses and development of effective allergic disease therapeutics in B cells.
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Introduction
The house dust mite is a major source of environmental
inhalation allergens involved in the pathogenesis of anaphylactic
type reactions in humans and animals [1,2]. The mite allergen
Dermatophagoides pteronyssinus group-2 (Der-p2) is a major allergen
and is highly correlated with asthma, atopic dermatitis and allergic
rhinitis. It has been estimated that 79.2% of patients with asthma,
wheezing and/or rhinitis have IgE antibodies to Der-p2 [3].
Recently, the Der-p2 allergen was found to show structural
homology with MD-2 suggesting that Der-p2 tends to be targeted
by adaptive immune responses because of its autoadjuvant
properties [4]. The structure of Der-p2 has been suggested to
provide a useful tool in the design of recombinant immunother-
apeutics for the group-2 allergens [5]. Mycobacterium bovis-
bacillus Calmette-Guerin (BCG) inoculation with Der-p2 has been
shown to cause a Th1-type immune response that hinders Der-p2-
induced allergic sensitization as well as the development of airway
inflammation [6]. Moreover, human T cells conditioned by the
proteolytic activity of mite allergen Der-p1 become empowered to
trigger enhanced IgE synthesis by B cells [7]. B cells are known to
exert a number of antibody-independent functions, capturing and
concentrating antigen, producing cytokines, influencing responses
of T cells and dendritic cells, contributing distinct functions during
the immune response, affecting lymphoid tissue structures, and
participating in tissue repair [8–10]. However, the precise action
and mechanism underlying the effects of Der-p2 on B cell
activation and immune response remain unclear.
Both innateandadaptivemechanismsarecommonlyused bythe
host to detect and eliminate pathogenic microbes. In addition to its
intrinsic capacities to mediate Toll-like receptors (TLR) expression
and microbial destruction, B cells also establish an important link
between the innate and adaptive branches of the immune system
[11–14]. Activation of B cells by bacterial lipopolysaccharide (LPS)
and peptidoglycan innate stimulation could induce TLR4 up-
regulation. Functional deficiency or genetic deletion of TLR4
increased the susceptibility to Haemophilus influenzae, Streptococcus
pneumoniae, and Klebsiella pneumoniae-related respiratory tract infec-
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to play a crucial role in protection from acute lethal infection by
Leptospira interrogans serovar Icterohaemorrhagiae and in the control of
leptospiral burden during sublethal chronic infection [17]. However,
Okumura and colleagues have shown that host TLR4 is a sensor for
Ebola virus glycoprotein and that resultant TLR4-related signalings
lead to the production of proinflammatory cytokines and suppressor
of cytokine signaling 1 (SOCS1), which play a role in the
immunopathogenesis of Ebola virus infection [18,19]. These
findings suggest that the activation of TLR4 seems to be required
for protective immunity against infections, but also mediates the
effects of systemic endotoxin infections. However, the effects of Der-
p2 on TLR4 inductionand TLR4-regulatedimmuneresponses inB
cells remain unclear.
Mitogen-activated protein (MAP) kinases have been shown to
be involved in all aspects of immune responses in mammalian
species, from the initiation phase of innate immunity, to activation
of adaptive immunity, and to cell death when immune function is
complete [20]. MAP kinase phosphatase (MKP)-1, which is
essential for the dephosphorylation/deactivation of MAP kinases
p38 and JNK, has been demonstrated to be an essential feedback
regulator of the innate immune response [21–24]. Nevertheless,
the roles of MAP kinases and MKP-1 in Der-p2-regulated B cell
activation and immune responses are still unknown. In view of the
importance of B cell activation in regulating immune repertoires
and responses, in this study, we investigated the precise actions and
mechanisms of Der-p2 on B cell activation and TLR4 induction.
The present study showed that Der-p2 specifically up-regulated
MKP-1 expression and activity in human B cells, which in turn,
resulted in p38/MAPK dephosphorylation and triggered TLR4
induction.
Results
Der-p2 activates proliferation and the expressions of
proinflammatory cytokines and TLR4 in human B cells
Purified recombinant Der-p2 isolated from mite culture by
affinity chromatography purification were shown in Coomassie
Blue staining (Fig. 1A-left panel) or recognized by anti-mite
Group-2 monoclonal antibodies C1 and C4 (Fig. 1A-right panel).
We further tested whether Der-p2 induces B cell proliferation,
which reflects the B cell activation. Der-p2 (1–10 mg/ml)
treatment of cells for 72 hours significantly increased the B cell
proliferation, which was determined by [
3H]-thymidine incorpo-
ration, in a dose-dependent manner (Fig. 1B). Both LPS (1 mg/ml)
and PMA (10 nM), as the positive controls, increased the B cell
proliferation (Fig. 1B). LPS inhibitor polymyxin B (PMB, 1 mg/ml)
markedly inhibited the LPS-induced cell proliferation, but did not
affect the Der-p2-induced response (Fig. 1B). In addition, LPS
markedly activated NO production in macrophages (J774 and
RAW264.7 cells), which could be reversed by PMB, but Der-p2
did not activate NO production in these macrophages (Fig. 1C).
Der-p2 markedly increased the mRNA expressions of proin-
flammatory cytokines IL-1b, CXCL10, IL-8, and TNF-a in
human B cells isolated from healthy donors (Fig. 1D) and patients
with AS or AD (Figs. 1E and 1F).
Der-p2 (1–5 mg/ml) could also markedly increase the TLR4
mRNA (Fig. 2A) and protein (Figs. 2B and 2C) expressions in B
cells in a dose- and time-dependent manner. Der-p2-blocking/
neutralizing antibody was capable of inhibiting the induction of
proinflammatory cytokines in Der-p2-treated B cells (data not
shown). Moreover, the cytofluorimetric analysis showed that
TLR4 was still expressed in B cells treated with Der-p2 in the
presence of TLR4-blocking/neutralizing antibody (Fig. 2D).
Der-p2 induces phosphorylation of ERK and
dephosphorylation of p38
As shown in Figure 3A, PD98059, a specific MAP kinase (MEK)
inhibitor, effectively enhanced the increased protein expressions of
TLR4 and its co-receptor MD2 in Der-p2-treated B cells.
However, SB203582, a specific p38 inhibitor, did not affect the
protein expressions of TLR4 and MD2 in Der-p2-treated B cells.
Der-p2 triggered the phosphorylation of ERK in human B cells in
a time-dependent manner (Fig. 3B). However, Der-p2 promptly
induced p38 dephosphorylation in B cells (Fig. 3C). Der-p2 did not
affect the activation of JNK (data not shown). These results
indicate that ERK signaling may exert a negative regulatory effect
on TLR4 expression in Der-p2-treated B cells.
Der-p2 induces MKP-1-regulated p38 dephosphorylation
and TLR4 expression
MAP kinase phosphatase (MKP-1) is known to play a pivotal
role in the deactivation of p38 and JNK. We found that Der-p2
effectively enhanced the phosphatase activity of MKP-1 (Fig. 4A)
and the expressions of MKP-1 mRNA (Fig. 4B) and protein
(Fig. 4C) in B cells. The Der-p2-enhanced MKP-1 and TLR4
mRNA expressions could be effectively reversed by actinomycin D
(Fig. 4D). However, Der-p2 did not affect the protein expressions
of phosphatases SHP-1 and SHP-2 in B cells. Moreover, we also
tested the effect of Der-p2 on other SHP-1 and SHP-2 expressions
in B cells (Fig. 4E and 4F).
We further found that Der-p2-triggered p38 dephosphorylation
was abolished by MKP-1 siRNA, but Der-p2-induced ERK
phosphorylation was not affected (Fig. 5A). The Der-p2-increased
TLR4 and MD2 protein expressions were markedly reversed in
siRNA-MKP-1-transfected B cells (Fig. 6A).
The results of immunoprecipitation assay also showed that there
was no crosstalk or interaction of MKP-1 with ERK during Der-p2
treatment (Fig. 5B). Moreover, activation of threonine or serine
MEK1/2 provided dual-specificity kinase phosphorylation for the
threonine and tyrosine residues on ERK. We found that the
phosphorylation of MEK1/2 on threonine or serine residues by
Der-p2 in B cells were not identical, which preferred the
phosphorylation of serine residue, but not threonine residue
(Fig. 5B).
Glucocorticoidsareknown toinducetheexpression ofMKP-1in
innate immune cells. As shown in Figure 6A, dexamethasone
markedly enhanced the increased protein expressions of TLR4 and
MD2 induced by Der-p2 (5 mg/ml) in human B cells. Transfection
of siRNA-MKP-1 could effectively abolish the augmentation of
TLR4 and MD2 protein expressions by dexamethasone plus Der-
p2 (Fig. 6A). Dexamethasone (20 mM) also significantly enhanced
the Der-p2-increased B cell proliferation, which could be effectively
reversed byneutralizing Der-p2antibody (Fig.6B). The efficiency of
transfection in B cells was nearly 90%, as shown in Fig. 6C.
Moreover, co-stimulatory molecules in B cells are up-regulated
during activation of B cells. The co-stimulatory molecules, such as
CD 86, CD 40, and CD 69, were up-regulated in B cells by Der-p2
stimulation (supplementary data, Figure S1).
Der-p2 triggers NF-kB activation in B cells
As shown in Figure 6D, Der-p2 (5 mg/ml) triggered significantly
greater NF-kB activation (3.2- to 4.3-fold) compared with the
control in human B cells. Antioxidants N-acetylcysteine (NAC,
2 and 5 mM) or pyrrolidinedithiocarbamate (PDTC) (10 mM)
effectively reversed the Der-p2-triggered NF-kB activation in B
cells. Moreover, dexamethasone (20 mM) could significantly
abrogate the Der-p2-triggered NF-kB activation in B cells
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ability to inhibit Der-p2-induced NF-kB activation in B cells.
Discussion
The results of the present study revealed a novel and important
finding which sheds light on the involvement of a signaling cascade
in the simultaneous activation of MEK1/2-ERK and dephos-
phorylation of p38 signaling in human B cells. Der-p2-specific up-
regulation of MKP-1, in turn, results in dephosphorylation and
inactivation of p38 MAPK. However, Der-p2 activated phos-
phorylation of ERK simultaneously. The ERK inhibitor,
PD98059 augments TLR4 expression, and is a negative regulators
of TLR4. Moreover, B cells evoke the Der-p2-induced expression
of the key cytokines, including IL-1b, CXCL10, IL-8 and TNF-a,
thus set in motion an adaptive immune response thereby
contributing significantly to host immune and defense responses.
(Fig. 7)
B cells are generated throughout life by differentiation from
hematopoietic stem progenitors and constitute approximately 15%
of peripheral blood leukocytes [25–27]. It has been shown that
human HSP60 induces native mouse B cells to proliferate and to
secrete IL-10 and IL-6 via the TLR4 and MyD88 signaling
pathway [28]. Hammad and colleagues found that the absence of
TLR4 in structural cells abolished house dust mite-driven allergic
airway inflammation [29]. A recent study by Trompette and
Figure 1. Mite allergen Der-p2 induces proliferation and expression of proinflammatory mediators in B lymphocyte. (A) Purified
recombinant Der-p2 proteins as indicated were determined by Western blotting. Left panel, purified recombinant protein Der-p2 0.25, 0.5 and 1 mg.
followed by staining with Coomassie Blue. Right panel, D. pteronyssinus antigen was recognized by C1 and C4 monoclonal antibody. (B)
[
3H]thymidine incorporation. B cells were pre-incubated with 1 mg/ml polymyxin B (PMB), an LPS inhibitor, and then treated with Der-p2 (1–10 mg/
ml), LPS (1 mg/ml) or PMA (10 nM) for 72 hours. (C) Macrophage J774 or RAW264.7 cells pretreated with PMB then further stimulated with Der-p2 or
LPS as indicated. Der-p2 did not activate NO production. PMB prevents LPS-induced NO production but not Der-p2. In D-F, B cells from healthy donor
(D), asthma patient (AS) and atopic dermatitis (AD) patients (E, F) were stimulated for 12 hours with a non-cytotoxic dose of Der-P2. The expressions
of proinflammatory mediators IL-1b , CXCL10, IL-8 and TNFa mRNA levels were detected by RT-PCR. Results shown are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0023249.g001
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adaptive immune responses is due to the fact that Der-p2
promotes TLR4 signalling and thus displays auto-adjuvant
properties [30]. Liu and colleagues have also shown that Der-p2
induces nitric oxide production in alveolar macrophage cell lines
via CD14/TLR4 [31]. In addition, a previous study by Poltorak
and colleagues showed that the mammalian TLR4 protein is
adapted primarily to subserve the recognition of LPS and
presumably transduces the LPS signal across the plasma
membrane [32]. Hoshino and colleagues have also demonstrated
that macrophages and B cells from TLR4-deficient mice do not
respond to LPS, indicating that TLR4 is the gene product that
regulates LPS response [33]. A recent study also showed that a
lack of TLR4 is associated with an even stronger inflammatory
response in the lung, and this suggests that TLR4 is a negative
regulator in noninfectious lung inflammation [34]. Gruber and
colleagues demonstrated that Der-p2 is composed of b-sheet and
random coil and exhibits crystal structural homology with MD-2
[35]. MD-2, which is physically associated with the extracellular
part of TLR4, is necessary for the intracellular signaling cascade
after LPS binding. However, the role of B cells in enhancing host
immune and defense response against invading mite allergens is
still unclear. The molecular basis for B cell activation and TLR4/
MD-2 induction in human B cells under Der-p2 exposure also not
completely understood. The present work found that the B cell
activation and proliferation and TLR4/MD2 expressions in
human B cells could effectively be induced by both Der-p2 and
LPS. Both TLR4 and MD-2 appear to be essential for B cell
responses to Der-p2, at least with respect to the induction of
immune mediators that are associated with chronic inflammation
or recurrent infection disease. Moreover, proinflammatory
cytokines, such as IL-1, IL-8, CXCL10, IL-6, and TNF-a, are
known to be released within hours after inflammation challenge
and serve as unspecific alarm signals, as they are released during
viral infection, asthma and atopic dermatitis. Here, we found that
Der-p2 could also markedly induce the expressions of proin-
flammatory cytokines in human B cells. Taken together, these
findings indicate that Der-p2 is capable of triggering B cell
activation and TLR4 induction in human B cells. The induced
Figure 2. Mite allergen Der-p2 up-regulates TLR4 expression in
human B cells. Human B cells from healthy donor, AS, AD or cell line
CESS were treated with Der-p2 (1–5 mg/ml) for 4–24 hours. The TLR4
mRNA (A) and protein (B-C) expressions in B cells were determined by
RT-PCR and Western blotting, respectively. (D) Cytofluorimetric analysis
of TLR4 expression on B cells lines CESS treated with Der-p2. B cells
were treated with Der-p2 (5 mg/ml) with or without blocking/
neutralizing TLR4 antibody for 24 hours. Inside plot shows TLR4
expression in B cells from AS patient treated with Der-p2. Results
shown are representative of four independent experiments.
doi:10.1371/journal.pone.0023249.g002
Figure 3. The changes of MAPK ERK and p38 phosphorylation
and TLR4 protein expression in Der-p2-treated B cells. In A, B
cells from AD patient and cell line CESS were cultured in serum-free
medium and treated with Der-p2 (1 mg/ml) at the indicated times. Cell
lysates were blotted and immunostained with anti-human phospho-
p38, p38, phospho-ERK, and ERK antibodies. In B, human B cells were
treated with Der-p2 (1 mg/ml) for 24 hours in the presence or absence
of ERK inhibitor PD98059 (20 mM) or p38 inhibitor SB203580 (20 mM).
TLR4 and MD2 protein expressions were assessed by Western blotting.
Results shown are representative of at least four independent
experiments.
doi:10.1371/journal.pone.0023249.g003
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Der-p2 infection.
MAP kinases are critical mediators of innate immune responses.
MKP-1, a threonine/tyrosine dual-specificity phosphatase, effi-
ciently suppresses MAP kinases p38 and JNK phosphorylation in
murine macrophages and other cell types [36–40]. MKP-1 has
been demonstrated to be a pivotal feedback control regulator
of the innate immune responses and plays a critical role in
suppressing endotoxin shock [41]. Bhattacharyya and colleagues
have shown that dexamethasone inhibits LPS-induced TLR4-
mediated inflammatory responses in macrophages through the
glucocorticoid receptor-related MKP-1-induced p38 inhibition
[42]. Wang and colleagues have further found that dexameth-
asone induces the expression of MKP-1 in vivo, and protected mice
from mortality caused by a relatively high dose of LPS [43].
Dexamethasone has also been shown to profoundly induce MKP-
1 expression in epithelial cells which results in repression of the
p38 MAPK pathway, leading in turn to repression of the TNFa-
induced NF-kB-dependent transcription [44]. In the present study,
we demonstrate that Der-p2 induces phosphorylation of ERK1/2,
as well as dephosphorylation of p38/MAPK in human B cells
under Der-p2 exposure. Der-p2 did not affect the expression of
JNK in B cells. ERK inhibitor PD98059 effectively enhanced Der-
p2-induced TLR4 expression in B cells, indicating that ERK
may be a negative regulator of TLR4 induction. The upstream
regulator of ERK, MEK1/2, can activate p44 and p42 ERK/
MAP kinase by phosphorylation of both threonine and tyrosine
residues at sites located within the activation loop of kinase
subdomain VIII. We further found that Der-p2 could activate the
phosphorylation of MEK1/2 at serine but not at threonine residue
site in human B cells. Moreover, the present work also found that
knockdown MKP-1 by siRNA effectively reversed p38 dephos-
Figure 4. Der-p2 activates MKP-1 phosphatase activity and gene expression in human B cells. In A, B cells (CESS) were treated with Der-
p2 (1 mg/ml) for various time intervals, and then the phosphatase activity of MKP-1 was detected as described in Materials and Methods. In B and C, B
cells from healthy donor, AS patient, AD patient, or cell line CESS were stimulated with Der-p2 (1 and 5 mg/ml) for 3 h and 24 h, and then the MKP-1
mRNA (B) and protein (C) expressions were detected by RT-PCR and Western blotting, respectively. In D, B cells were treated with Der-p2 for 3 hours
in the presence or absence of actinomycin D (ACT), and then MKP-1 and TLR4 mRNA expressions were assessed by RT-PCR. In E and F, B cells (CESS or
primary cells from AD patient) were treated with Der-p2 (1 mg/ml) for 10 min to 24 hours, and then the MKP-1, SHP1, and SHP2 protein expressions
were detected by Western blotting. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0023249.g004
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cells. These finding demonstrate that MKP-1 is involved in the
dephosphorylation of p38 and TLR4/MD2 expressions induced
by Der-p2 in B cells. Moreover, dexamethasone-enhanced TLR4/
MD2 induction by Der-p2 could also be abrogated by siRNA
MKP-1, suggesting a novel cellular and molecular mechanism for
dexamethasone in the regulation of innate immune responses.
In conclusion, this study demonstrates for the first time that
Der-p2 is capable of triggering human B cell activation and TLR4
induction. Der-p2 markedly induced the expressions of several key
cytokines including IL-1b, CXCL10, IL-8, and TNF-ain B cells.
Der-p2 could also enhance NFkB activity, indicating that Der-p2
may exert its influence through NFkB activation to induce the
production of proinflammatory cytokines. Moreover, Der-p2
specifically up-regulated MKP-1 expression and activity in human
B cells, which in turn, resulted in p38/MAPK dephosphorylation,
triggering TLR4 induction.
Materials and Methods
Cells and Culture
Human B cell line CESS cells were a gift from Dr. KI Lin
(Academia Sinica, Taiwan). Cells were maintained in RPMI-1640
medium containing 10% heat inactivated FCS and strepto-
mycin/penicillin in a humidified 5% CO2 atmosphere. In some
experiments, the human B cells were isolated from the blood of
Figure 5. MKP-1 specifically regulates Der-p2-induced dephosphorylation of p38 but not phosphorylation of ERK in human B cells.
In A, B cells from cell line CESS or AD patient were treated with Der-p2 (5 mg/ml) for 24 h in the presence or absence of siRNA-MKP-1. The
phosphorylated and total protein expressions of ERK and p38 MAPK were determined by Western blotting. In B, B cells from AD or AS patients were
treated with Der-p2 for 24 h. The cellular immunoprecipitation was prepared using a MKP-1 antibody, and then immunoblotting with phospho-ERK
antibody was determined. In C, B cells were cultured in serum-free medium and treated with Der-p2 for 60 minutes. The cellular immunoprecipitation
was prepared using a MEK1/2 antibody, and then immunoblotting with serine or thronine phosphorylation antibodies were determined. The
immunoblots were also reprobed for total MEK1/2 protein detection. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0023249.g005
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and from patients with asthma or atopic dermatitis after obtaining
written informed consent. The study was approved by the Research
Ethics Committee of Taichung Veterans General Hospital.
Ethics statement
State the consent and approved documents was obtained. All
animal experiments were performed according to the National
Institutes of Health Guide for Care and Use of Experimental
Animals and approved by National Chung Hsing University
Animal Care and Use Committee (Animal welfare assurance
No. NCHU-98-102). In addition, all human sample subjects
provided informed consent, the protocols, and allresearch involving
human participants were approved by the Institutional Review
Board of Taichung Veterans General Hospital. State the ethics
committee specifically approved document (TCVGH-C07261-3).
Measures were taken to clear from the approved documents were
obtained that had accumulated over the past two years.
Purification of naive B cells
Human PBMCs were prepared by density centrifugation
(Ficoll-Paque). In some experiments, mouse spleen cell suspen-
Figure 6. Dexmethasone augments Der-p2-induced MKP-1-regulated TLR4/MD2 expressions and B cell proliferation. In A, B cells
(CESS) or primary B cells transfected with siRNA-MKP-1 or control siRNA (scrambled) were treated with Der-p2 for 24 h in the presence or absence of
dexamethasone (Dex, 20 mM). TLR4/MD2 protein expressions were determined by Western blotting. Bacterial lipopolysaccharide or PMA were used
as a positive control. B, B cells (CESS) were treated with Der-p2 (5 mg/ml) for 72 hours in the presence or absence of dexamethasone (Dex, 20 mM) or
neutralizing Der-p2-antibody (B/N-Der-p2-Ab, 20 mg/ml), and then the cell proliferation was determined by [
3H]-thymidine incorporation assay. Data
are presented as mean6SEM (n=5). In C, the efficiency of transfection in B cells was nearly 90%. In D, Der-p2 activates NFkB activity in human B cells.
Human B cells from AD patient or CESS were transiently transfected with the NFkB-luciferase reporter plasmid constructs. NFkB activity was detected
24 hours after treatment with Der-p2 (5 mg/ml) in the presence or absence of N-acetylcysteine (NAC, 2 and 5 mM) or pyrrolidinedithiocarbamate
(PDTC) (10 mM). In E, transfected B cells were treated with Der-p2 (5 mg/ml) for 24 hours in the presence or absence of dexamethasone (Dex, 20 mg/
ml). Data are presented as mean6SEM (n=5). # p,0.05 vs. control group.
doi:10.1371/journal.pone.0023249.g006
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buffer (Sigma-Aldrich). B cells were then purified by negative
selection with a B cell isolation kit containing biotin-conjugated
monoclonal antibodies to CD43, CD4, and Ter-119 (Miltenyi
Biotec). This procedure routinely yielded B cell preparations that
were .95% positive for the B220 marker as determined by
FACS analysis.
Der-p2 preparation
Purified recombinant protein Der-p2 was prepared as previ-
ously described [6]. The endotoxin contamination was tested by
Pyrochrome Limulus Amebocyte Lysate assay (Associates of Cape
Cod). The endotoxin level was low (0.007460.01 ng/mg).
Proliferation assay
B cells were cultured with or without Der-p2 or LPS (Escherichia
coli strain 055:B5; Sigma-Aldrich) treatments. Cells were pulsed
with 1 mCi of [
3H]thymidine and incubated for a further 24–72 h,
and then were harvested. The incorporation of [
3H]thymidine was
measured by scintillation counting.
Nitric oxide (NO) production
NO production was estimated by measuring nitrite accumula-
tion in culture medium using the Griess method.
Flow cytometric analysis
Both surface activation and costimulatory molecules were
detected by flow cytometry. B cells (2610
5/well) were cultured
with FITC-conjugated anti-mouse CD86, CD80, or CD69 or PE-
conjugated CD40, TLR4 (BD PharMingen) for 30 min on ice.
After washing, stained cells were quantified using the FCScan
system and CellQuest software (BD Biosciences).
Reverse transcription-polymerase chain reaction (RT-PCR)
Cells were homogenized with 1 ml of TRIzol reagent (Invitro-
gen). The total RNA was isolated according to the manufacturer’s
protocol. The first standard cDNA was synthesized by the
extension of (dT) primers with 200 units of SuperScript II reverse
transcriptase (Invitrogen) in a mixture containing 1 mg of total
RNA digested by RNase-free DNase (2 units/mg of RNA) for
15 min at 37uC. Then the cDNA served as a template in a PCR
using the PerkinElmer DNA Thermal Cycler (model 480). The
sense primers (59 or 39) were: MKP-1, 59-GCTGTGCAGCAAAC-
AGTCGA-39,IL1-b 59-AAACAGATGAAGTGCTCCTTCCAG-
G; TNFa,5 9-GGCTCCACCCTCTCTCCCCTG; TLR4, 59-CT-
TATAAGTGTCTGAACTCCC;IL-8,59-TTGGCAGCCTTCC-
TGATTTCT-39;b-actin5-GATGATGATATCGCCGCGCT;C-
XCL10, 59-GCTTAGACATATTCTGAGCCTAC-39,a tac o n c e n -
tration of 0.4 mM. The amplification cycles were as follows: 94uCf o r
60 s, 55uCf o r6 0s ,a n d7 2 uC for 90 s. Then the PCR products were
subjected to electrophoresis on a 2% agarose gel after 30 cycles. The
electrophoresis products were visualized by ethidium bromide
staining. The mRNA of b-actin was used to control sample integrity
and loading.
Western blotting
Whole cell lysates were prepared as described previously [45].
After blocking, the blots were incubated with antibodies for anti-
human TLR4, MD2, p-ERK, ERK, p-p38, p38, MKP-1, and b-
actin (Santa Cruz Biotechnology) in PBS with 0.1% Tween 20 for
1 h followed by three 10-min washes in PBS with 0.1% Tween 20.
The membranes were then incubated with horseradish peroxi-
dase-conjugated secondary antibodies for 60 min. Detection was
performed with ECL (Amersham), and chemiluminescence was
measured by Kodak X-Omat film.
MKP-1 phosphatase activity
MKP-1 activity was measured using immunoprecipitated MKP-
1. Cells were lysed in lysis buffer, and 500 mg of supernatant
protein was incubated with 2 mg of antiphosphorylated MKP-1
antibody or IgG at 4uC for 2 h, followed by incubation with
protein A/G PLUS overnight. Immunoprecipitates were washed
three times with cell lysis buffer. Phosphatase activities of
immunoprecipitated MKP-1 were analyzed using pNPP protein
phosphatase assay kit (AnaSpec).
Transfection, luciferase reporter, and siRNA
Cells were transfected with plasmid using Lipofectin (Invitrogen
Life Technologies). For promoter reporter assays, cells were
cotransfected with either pNF-kB-Luc or pRL-TK (Renilla
luciferase control). Firefly and Renilla luciferase activity was
determined by Dual Luciferase Kit (Promega Corporation)
following the manufacturer’s protocol. A specific siRNA (MWG
Biotech, Germany) was used to specifically knock-down the MKP-
Figure 7. Schematic diagram of the role of TLR4 in the context
of Der-p2-induced B cells activation. The signaling cascade
involved in simultaneous activation of MEK1/2-ERK and dephosphory-
lation of p38 signaling in human B cells. As indicated, Der-p2 specific
up-regulation of MKP-1 results in dephosphorylation and inactivation of
p38 MAPK. However, Der-p2 activated phosphorylation of ERK
simultaneously. The ERK inhibitor, PD98059 augments TLR4 expression,
and was found to be a negative regulator of TLR4. Moreover, B cells
evoke the Der-p2-induced expression of the key cytokines, including IL-
1b, CXCL10, IL-8 and TNF-a, thus setting in motion an adaptive immune
response and thereby contributing significantly to host immune and
defense responses.
doi:10.1371/journal.pone.0023249.g007
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collected and analyzed for luciferase activity or protein expression,
respectively.
Statistical Analysis
The values are presented as mean6SEM. All analyses were
performed by analysis of variance followed by Fisher’s least
significant difference test. P values less than 0.05 was considered
statistically significant.
Supporting Information
Figure S1 Der-p2 up-regulated costimulatory molecule
expression. B cells from C57BL/6J mice were treated with Der-
p2 (5 mg/ml). After 24 hours, the cells were stained with antibody
FITC-conjugated anti-mouse CD86, CD80, or CD69 or PE-
conjugated CD40, and detected by flow cytometry. The block line
shows control unstimulated cells, and the red line shows Der-p2
(5 mg/ml)-treated cells. The pink line shows Der-p2 (5 mg/ml)
combined with Dex 20 mM, and the green line shows Der-p2
(5 mg/ml) combined with PD98059 (20 mM). The results are
representative traces of at least three experiments.
(TIF)
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